Nutriband (NTRB) Stock Price, News & Analysis

Company Overview

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Key Stats

• Today's Range: $6.21 to $6.44
• 50-Day Range: $6.17 to $10.72
• 52-Week Range: $3.72 to $11.78
• Volume: 13,090 shs
• Average Volume: 36,853 shs
• Market Capitalization: $71.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Nutriband Stock Analysis - MarketRank™

Nutriband scored higher than 48% of companies evaluated by MarketBeat, and ranked 622nd out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nutriband has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Nutriband has a consensus price target of $13.00, representing about 103.8% upside from its current price of $6.38.

Amount of Analyst Coverage

Nutriband has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nutriband are expected to grow in the coming year, from ($0.60) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nutriband is -7.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nutriband is -7.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nutriband has a P/B Ratio of 11.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.10% of the float of Nutriband has been sold short.

Short Interest Ratio / Days to Cover

Nutriband has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nutriband has recently increased by 143.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nutriband does not currently pay a dividend.

Dividend Growth

Nutriband does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.10% of the float of Nutriband has been sold short.

Short Interest Ratio / Days to Cover

Nutriband has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nutriband has recently increased by 143.49%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.50

News Sentiment

Nutriband has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Nutriband this week, compared to 1 article on an average week.

Search Interest

2 people have searched for NTRB on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Nutriband to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nutriband insiders have not sold or bought any company stock.

Percentage Held by Insiders

54.09% of the stock of Nutriband is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.70% of the stock of Nutriband is held by institutions.

NTRB Stock Analysis - Frequently Asked Questions

How have NTRB shares performed this year?

Nutriband's stock was trading at $4.71 on January 1st, 2025. Since then, NTRB shares have increased by 35.5% and is now trading at $6.38.

How were Nutriband's earnings last quarter?

Nutriband Inc. (NASDAQ:NTRB) posted its quarterly earnings data on Friday, May, 30th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. The company earned $0.67 million during the quarter, compared to analysts' expectations of $0.71 million. Nutriband had a negative trailing twelve-month return on equity of 68.25% and a negative net margin of 415.93%.

When did Nutriband's stock split?

Nutriband shares split on Monday, August 15th 2022.The 13-6 split was announced on Monday, August 15th 2022. The newly minted shares were payable to shareholders after the market closes on Monday, August 15th 2022. An investor that had 100 shares of stock prior to the split would have 217 shares after the split.

Who are Nutriband's major shareholders?

Nutriband's top institutional shareholders include Consolidated Portfolio Review Corp (0.09%).

How do I buy shares of Nutriband?

Shares of NTRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nutriband own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nutriband investors own include Jiuzi (JZXN), AMC Entertainment (AMC), Aridis Pharmaceuticals (ARDS), Avenue Therapeutics (ATXI), Esports Entertainment Group (GMBL), Moleculin Biotech (MBRX) and ARMOUR Residential REIT (ARR).

Company Calendar

• Last Earnings: 5/30/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 9/09/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NTRB
• CIK: 1676047
• Web: nutriband.com
• Phone: (407) 377-6695
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nutriband: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +103.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.48 million
• Net Margins: -415.93%
• Pretax Margin: -415.93%
• Return on Equity: -68.25%
• Return on Assets: -60.40%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 3.71
• Quick Ratio: 3.48

Sales & Book Value

• Annual Sales: $2.14 million
• Price / Sales: 33.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 11.00

Miscellaneous

• Outstanding Shares: 11,150,000
• Free Float: 5,121,000
• Market Cap: $71.14 million
• Optionable: Not Optionable
• Beta: 1.13